Abstract
Amphotericin B therapy is hampered by numerous adverse effects but remains the treatment of choice for disseminated fungal infections. A new form of amphotericin B delivery, which utilizes liposome vesicles, is currently under investigation. Preliminary evidence suggests that liposome-encapsulated amphotericin B has a wider therapeutic index than free amphotericin B and allows for the use of larger total doses. The mechanism of reduced toxicity and enhanced activity may be associated with a liposome donor effect, an erythrocyte protective effect, and a liposome-targeting ability. Liposome-encapsulated amphotericin B tends to be entrapped or taken up by organs rich in reticuloendothelial cells--a particular advantage since disseminated fungal infections localize in these areas. This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1097-1101 |
| Number of pages | 5 |
| Journal | Reviews of Infectious Diseases |
| Volume | 10 |
| Issue number | 6 |
| State | Published - Nov 1988 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
Cite this
Liposome-encapsulated amphotericin B : a promising new treatment for disseminated fungal infections. / Wiebe, V. J.; DeGregorio, M. W.
In: Reviews of Infectious Diseases, Vol. 10, No. 6, 11.1988, p. 1097-1101.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Liposome-encapsulated amphotericin B
T2 - a promising new treatment for disseminated fungal infections.
AU - Wiebe, V. J.
AU - DeGregorio, M. W.
PY - 1988/11
Y1 - 1988/11
N2 - Amphotericin B therapy is hampered by numerous adverse effects but remains the treatment of choice for disseminated fungal infections. A new form of amphotericin B delivery, which utilizes liposome vesicles, is currently under investigation. Preliminary evidence suggests that liposome-encapsulated amphotericin B has a wider therapeutic index than free amphotericin B and allows for the use of larger total doses. The mechanism of reduced toxicity and enhanced activity may be associated with a liposome donor effect, an erythrocyte protective effect, and a liposome-targeting ability. Liposome-encapsulated amphotericin B tends to be entrapped or taken up by organs rich in reticuloendothelial cells--a particular advantage since disseminated fungal infections localize in these areas. This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.
AB - Amphotericin B therapy is hampered by numerous adverse effects but remains the treatment of choice for disseminated fungal infections. A new form of amphotericin B delivery, which utilizes liposome vesicles, is currently under investigation. Preliminary evidence suggests that liposome-encapsulated amphotericin B has a wider therapeutic index than free amphotericin B and allows for the use of larger total doses. The mechanism of reduced toxicity and enhanced activity may be associated with a liposome donor effect, an erythrocyte protective effect, and a liposome-targeting ability. Liposome-encapsulated amphotericin B tends to be entrapped or taken up by organs rich in reticuloendothelial cells--a particular advantage since disseminated fungal infections localize in these areas. This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.
UR - http://www.scopus.com/inward/record.url?scp=0024119161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024119161&partnerID=8YFLogxK
M3 - Article
C2 - 3060940
AN - SCOPUS:0024119161
VL - 10
SP - 1097
EP - 1101
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 6
ER -